Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Advanced Cancer|Metastatic Cancer|Malignant Neoplasm of Colon|Malignant Neoplasm of Lung|Malignant Neoplastic Disease
DRUG: MRTX849|DRUG: BI 1701963
Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation, Number of participants with treatment related adverse events, 20 months|Evaluate Pharmacokinetics of the combination regimen, Blood plasma concentration, 20 months|Establish Maximum Tolerated Dose, Number of patients with dose limiting toxicity, 12 months
Evaluate preliminary clinical activity of the combination regimen, Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST), 20 months
This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.